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Purpose: To assess the agreement between cardiac output estimated by two dimensional 
echocardiography and bioreactance methods at rest and during dobutamine stress test in heart 
failure patients with preserved left ventricular ejection fraction (HFpEF).
Methods: Haemodynamic measurements were assessed in 20 stable HFpEF patients (12
females; aged 61+7 years) using echocardiography and bioreactance methods during rest and 
dobutamine stress test at increment dosages of 5,10,15 and 20 μg/kg/min until maximal dose
was achieved or symptoms and sign occurred i.e. chest pain, abnormal blood pressure 
elevation, breathlessness, ischemic changes, or arrhythmia.
Results: Resting cardiac output and cardiac index estimated by bioreactance and
echocardiography were not significantly different. At peak dobutamine stress test cardiac
output and cardiac index estimated by echocardiography and bioreactance were significantly 
different (7.06 1.43 vs 5.71 1.59 L/min, p<0.01; and 4.27 0.67 vs 3.43 0.87 L/m2/min; 
p<0.01) due to the significant differences in stroke volume. There was a strong positive
relationship between cardiac outputs obtained by the two methods at peak dobutamine stress
(r=0.79, p<0.01). The mean difference (lower and upper limits of agreement) between 
bioreactance and echocardiography cardiac outputs at rest and peak dobutamine stress were ­
0.45 (1.71 to -2.62) L/min and -1.35 (0.60 to -3.31) L/min respectively.
Conclusion: Bioreactance and echocardiography methods provide different cardiac output 
values at rest and during stress thus cannot be used interchangeably. Ability to continuously
monitor key haemodynamic variables such as cardiac output, stroke volume and heart rate is 






     





     
    
  
    
   
     
   
  
      
 
 




     
       
    
  
    
 
Introduction
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome associated with 
poor prognosis; increased mortality and hospitalization and reduced quality of life and 
functional independence [1, 2]. HFpEF is characterised by clinical signs of heart failure with 
left ventricular ejection fraction (LVEF) over 50% [3]. The heterogeneity of HFpEF syndrome 
makes its diagnosis and treatment challenging. HFpEF is a slowly progressive multifactorial 
clinical syndrome where there is a close interaction of aging and co-morbitidities with
cardiovascular and systemic mechanism resulting in clinical symptoms charaterised by low
functional reserve and reduced cardiac performance. Recently, there has been a growing 
interest about knowledge of cardiac output and cardiac performance both at rest and after stress 
in patients of HFpEF. Computation of LVEF involves cardiac stroke volume which in turn 
affects the cardiac output. Cardiac output, defined as the amount of blood volume the heart
pumps through the systemic circulation over a period measured in liters per minute[4], is an
important measure of cardiac performance providing an indication of systemic oxygen delivery
and global tissue perfusion [5, 6]. The average cardiac output for a healthy adult is 
approximately 5–6 l /min [5], increasing four-folds in untrained individuals, and up to
sevenfold in trained athletes [7]. 
Optimal strategy to diagnose HFpEF should incorporate haemodynamic evaluation at rest and 
in response to stress-induced increase in filling pressures [3]. In patients with heart failure,
cardiac power output obtained during stress testing, either by physiological or pharmacological 
stimulations, coupled with blood pressure, is the strongest predictor of mortality and functional
capacity [8, 9].
Since the discovery of invasive cardiac output measurement by Adolf Fick in 1870[10], and
the subsequent introduction a century later, of the Swan Ganz pulmonary artery catheterisation
based on bolus thermodilution [11], other newer minimally invasive and non-invasive
techniques have been discovered. These newer techniques are such as pulse contour analysis, 
oesophageal doppler, inert gas rebreathing, thoracic bioimpedance, thoracic bioreactance and 
echo doppler method [12] limit risks associated with infections, arrhythmia, complications of 




   




    
    
  
 
   
 
    
    
 
    
      
   





   
 
 
     
   
      
     
However, their acceptability has been limited by inaccuracy and unreliability [12, 14]. An ideal 
cardiac output monitor should be easy to use, valid, reliable, reproducible, non-invasive, cheap 
with fast response time[12, 15]. Recently there has been a lot of clinical and research focus on
two dimensional echocardiography and bioreactance derived cardiac output monitoring in 
various clinical scenario [16-18].
Echocardiography has emerged as an important tool in the diagnosis, management and 
prognostication of patients of heart failure and is the most utilized non-invasive tool in clinical 
and research setting [19, 20]. 2-Dimensional (2D) echocardiography is regularly used for the 
assessment of cardiac output in various clinical settings especially in critical care settings and 
in cardiology. It has been extensively validated against the gold standard thermodilution 
technique both at rest and after exercise [21, 22]. . The bioreactance derived cardiac output
method has been validated with the invasive gold standard method of thermodilution for
assessing cardiac output [23]. Previous reports have also shown that bioreactance demonstrated 
acceptable test-retest reliability for estimating cardiac output and stroke volume at rest and
after physiological stress test in healthy individuals [24]. Although bioreactance and 2D 
echocardiography have been widely studied, no studies have compared both techniques
directly. Therefore, the aims of the present study are (1) to compare resting and dobutamine
induced stress bioreactance and echocardiography derived cardiac outputs in stable patients of 
HFpEF and (2) to assess the agreement between the bioreactance and 2D echocardiography
methods. 
Methods
This was a single centre, prospective observational, direct comparison study between 
bioreactance and transthoracic echocardiography methods for measuring cardiac output at rest
and at peak stress.
Participants 
Twenty stable HFpEF patients  (12 females and 8 males) participated in the study, which was
conducted at the Sengupta Hospital and Research Institute, Ravinagar, Nagpur, India. Ethical
approval for this study was provided by an Independent Research Ethics Committee affiliated
to hospital. Clinically stable HFpEF patients who were willing to give informed consent and 




   
     
   
      
    






    
 
     
 
 
    
     
    
      
    
   
  
 
    
    
 
                                           
 
disease, cardiac arrhythmias, myocardial infarction, percutaneous coronary intervention and/or
bypass graft surgery over the past 3 months, primary pulmonary hypertension and active 
malignancy were excluded from the study. Subjects were instructed to abstain from eating for
at least 2 hours before the test and from vigorous exercise 24 h prior to the test. Subjects were 
also instructed not to consume alcohol or caffeine containing foods and beverages on test days.
Upon arrival at the laboratory, participants were informed of the benefits and potential risks of
the study and they subsequently provided a written informed consent. Participants were asked
to lay in a supine position for 10 min. Blood pressure was measured in duplicate in the brachial
artery of participant’s non-dominant arm. 
Study protocol and measurements
Heart rate, stroke volume, cardiac output and cardiac index  were recorded using bioreactance 
and transthoracic echocardiography simultaneously at rest and at peak dobutamine infusion
stress test with incremental dose of 5,10,15, and 20 ug/Kg/min in 3 minutes stages. The test 
was terminated when the participant achieved the targeted dose of dobutamine infusion, or 
symptoms and signs i.e. breathlessness and palpitation were present, or patient desired to stop
assessment for any reason. Atropine injection was not used in the protocol.
Bioreactance 
The bioreactance system used in this study was NICOM (Cheetah Medical, Delaware, USA). 
NICOM provides cardiac output monitoring non-invasively and uses time-dependent relative
phase shifts of an oscillating current traversing the thoracic cavity [23]. The NICOM system 
uses a radiofrequency generator that creates a high-frequency current injected across the 
thorax. These currents are passed through four dual-surface electrodes which are attached over
the trapezius muscle on either side of the upper body and lower posterior torso lateral to the
margin of the latissimus dorsi musculature. The signals are passed through these electrodes and
recorded back and then processed digitally. The signal processing unit of the system determines 
the relative phase shift between the input signals relative to the output signals. This phase shift 
is due to instantaneous changes in blood flow in the aorta. Cardiac output (QT) is subsequently 
calculated by: 
QT 1⁄4 ðC VET DU=dtmaxÞ HR 




    
     




   
   
   
  
  
      
       
     
    
   
 




   
 
 
   
    
    
      
determined from the bioreactance and electrocardiogram signals, Dɸ/dtmax is the relative
phase shift of current, and HR is heart rate. The value of C has been optimized in prior studies 
and is dependent on patient’s age, gender and body size. 
Transthoracic echocardiography
Transthoracic echocardiography (TE) was performed using a commercially available 
echocardiographic system, Vivid E95 (General Electric Company, Vingmed Ultrasound AS,
Horten, Norway). A single experienced operator performed all the data acquisitions. Images
were obtained in the parasternal short‐axis view at 3 left ventricular (LV) levels: basal, mid, 
and apical, and in apical 4‐, 3‐, and 2‐chamber views, with images taken at rest and at peak 
dobutamine infusion. An average of three beats were captured for analysis. Echocardiographic 
assessment was done at 50-70 frame rate/seconds. A 17‐segment model of the LV was used for
analysis. In parasternal long axis view, the LV out flow tract measurement was taken in the 
phase of systole according to the chamber guidelines. Pulsed-wave doppler of the LV out flow
tract was recorded from either apical five-chamber or long-axis view depending on best
alignment of the doppler beam to flow direction. The stroke distance was measured by tracing
of the flow profile which produces the velocity time integral (VTI). Stroke volume was then
calculated by the formula:
Stroke volume = (LVOT diameter)2 x 0.785 X LVOT VTI, where LVOT is left ventricular 
outflow tract [25-27].
Cardiac output and cardiac index were calculated by the formulae: 
Cardiac output (L/min) = Stroke volume (ml/beat) x heart rate (beats/min)
Cardiac index (L/min/m2) = Cardiac output (L/min) / body surface area (m2)
Dobutamine stress test
Dobutamine stress test (DSE) was performed using the protocol previously defined.[18]
Dobutamine was administered by a peripheral intravenous line without any foreseeable side
effects in a medically controlled environment. Before the test, patients were asked to stop any




   
  
   
 
 
   
      
   
   
     
   
      
     
  
 
     
        
        
   
  
   
      
  
   
 
     
prior to the test. Dobutamine was infused intravenously in 3‐minute intervals, with gradual 
dose titration from 5,10,15 and 20 μg/kg/min until maximal dose was achieved or symptoms
and sign occurred i.e. chest pain, abnormal blood pressure elevation, breathlessness, ischaemic
changes, arrhythmia or patients ability to tolerate the drug. All the standard echocardiographic 
views were taken before starting the DSE and at the time of peak tolerated dose.
Statistical analysis
Data are expressed as mean (±SD) unless otherwise stated. Normality of distribution was
evaluated using a Kolmogorov– Smirnov test. Independent t test was used to determine
significance between the bioreactance and dobutamine stress echocardiography. Paired 
samples t-test was used to assess differences between the two methods at rest and peak
dobutamine stress. To assess the relationship between the two methods Pearson's or
Spearman’s coefficient of correlation was used as appropriate. Bland–Altman plots were 
constructed to evaluate the mean difference and upper and lower limits of agreements (±2 SD 
of mean difference) between bioreactance and echocardiography methods. All statistical 
analysis was carried out using SPSS version 20 (SPSS Inc., Chicago, IL, USA) and R-3.0.0
programming tool (IBM, Chicago,IL:60606, USA) Data are expressed as mean  SD unless
otherwise stated and statistical significance was  indicated if p<0.05.
Results
Participants were aged 61  7 years, weight 67  15 kg, height 154  7 cm and body surface 
2area 1.66  0.19 m . The baseline parameters of the patient population are summarized in Table 
1. The NT- proBNP levels of the patient population was 960  1129 pg/ml. In all subjects a
stable bioreactance signal was obtained at rest and throughout the dobutamine stress test.
Resting heart rate estimated by bioreactance and 3-lead ECG accompanying echocardiography
were not significantly different. The average dose of dobutamine for all the participants was 
18.75 2.22 ug/kg/min. There was no significant difference in resting cardiac output and
cardiac index estimated by bioreactance and echocardiography (Table 2). There was a
moderate positive relationship between bioreactance and echocardiography derived cardiac
output at rest (r=0.56, p<0.01; Figure 1).
At peak dobutamine stress, there was no significant difference in heart rate. However, 




   
   
  
      
   
     
   
    
 
 
    
     
     
       
     
      
    
   
   
       
  
  
   
   
    
 
  
     
   
     
 
echocardiography (p<0.001, Table 2). There was a strong positive relationship between
bioreactance and echocardiography derived cardiac outputs at peak dobutamine stress (r= 0.79, 
p < 0.001; Figure 1).
The mean difference (lower and upper limits of agreement) between bioreactance and
echocardiography cardiac outputs at rest and peak dobutamine stress was -0.45 (1.71 to -2.62) 
L/min and -1.35 (0.60 to -3.31) L/min respectively (Figure 2A,2B). For stroke volume, the 
mean difference (with upper and lower limits of agreement) between the two methods at rest 
and peak dobutamine stress was-5.69 (19.8 to -31.2) ml/beat and -9.2 (9.59 to -27.99) ml/beat
respectively.
Discussion
The present study compared two non-invasive methods for estimating cardiac output i.e.
echocardiography and bioreactance at rest and after dobutamine stress test in stable patients
with HFpEF. This is the first study to investigate non-invasive hemodynamic monitoring using
both methods. . The important finding of the study is that at rest, both echocardiography and
bioreactance derived cardiac output and stroke volume were similar. At peak dobutamine
stress, bioreactance recorded lower cardiac output compared to echocardiography. However,
the calculated limits of agreement were wide and unacceptable, suggesting that the two
methods cannot be used interchangeably both at rest and peak stress. 
The usage of bioreactance technique for cardiac output assessment during rest and after
exercise has been earlier evaluated in chronic heart failure patients[28, 29] . In a recent study,
Rali et al. showed that the NICOM technology is not a reliable method for measuring cardiac 
output in patients with decompensated heart failure and cardiogenic shock when compared 
with indirect Fick’s thermodilution method[30]. The authors explained that bioreactance 
method is dependent on oscillation of electric current which passes through the thoracic cavity
and in patients with advanced heart failure, pulmonary and interstitial edema affects the 
passage of these signals. Also alteration in right sided and left sided preload seen in heart failure 
patients affect the intrathoracic impedance which in turn impacts the current phase shifts 
necessary to calculate SV and CO. However studies have also shown that bioreactance is useful
in evaluation of fluid responsiveness in critical care settings [31]. This may be important in
clinical scenario like in HFpEF patients where fluid hemodynamics and filling pressures




    
    
    
    
     
      
    
    
     
    
   
   
 
  
   
  
    
   
     
     
  
  
    
  




   
   
   
Echocardiography is a useful, and reliable method for estimating cardiac output in critically 
ill patients [21]. In a cohort of 38 mechanically ventilated patients, Mercado et al. showed that
echocardiography derived cardiac output correlated well with invasive swan-Ganz derived
cardiac output [21]. They used the pulse wave doppler of aortic blood flow in apical five-
chamber view to calculate cardiac output similar to the present study. Various studies have
shown that that cardiac output derived from aortic blood flow by pulse wave doppler using
apical five chamber view was better than that derived from signals from pulmonary or mitral
valves [32, 33]. Also in our study, we used the left ventricular out flow tract velocity time 
integral from echo to derive cardiac output. This method has been better than ejection fraction
derived cardiac output in patients with advanced heart failure for prediction of outcomes [34]. 
However, the accuracy of echo derived cardiac output is limited by errors in determining cross
sectional area of LVOT[34]. So a careful assessment of LVOT cross sectional area is 
mandatory.
At peak dobutamine stress, there was no interference in signals and no artifacts seen in our 
study. Both cardiac output methods used in the study were non-invasive and easy to operate. 
Bioreactance provides continuous cardiac output monitoring, is patient friendly and does not
require a familiarization procedure and may have wider application, especially in cardiology
settings where cardiac output monitoring is important. However the only challenge can be in
patients who have implanted cardiac device as it may interfere with the signals [35]. Also,
bioreactance cardiac output is based on the assumption that the area under the flow pulse is 
proportional to the product of peak flow and ventricular ejection time. So in conditions of low
flow status, the readings may have low accuracy[36].
The present study has few limitations. First, the gold standard Fick’s method of assessment of 
cardiac output was not included. Fick’s principle involves invasive procedure associated with
complications as discussed earlier which may not be suitable in HFpEF patients. Applying 
the gold standard of Fick’s method to this study could have raised ethical concerns as there 
would have been increased risk to the study’s population due to its invasive nature. However, 
both techniques have been previously validated against the invasive gold standard methods,
that is thermo-dilution and Fick’s techniques. Results revealed acceptable levels of agreement
between bioreactance and echocardiography with these invasive methods.(21-23) Second, this
is a single centre study with a small sample size. However, this is the first study showing the 






     
    
   
  
    
    
 
   
      




    












pharmacological stress in patients with HFpEF. 
In conclusion, bioreactance and echocardiography provide different cardiac output estimates, 
especially at pharmacological stress exercise, therefore cannot be used interchangeably in
patients with HFpEF. Technological differences, alteration in loading conditions, complex
haemodynamics of HFpEF and changes in pulmonary vascular reserve seen in HFpEF are 
likely to explain discrepancies in cardiac output estimates between the bioreactance and 
echocardiography derived cardiac outputs. Future studies are warranted to assess performance
of bioreactance and echocardiography against the gold standard procedure in various cardiac
conditions. 
This is the first study to compare cardiac output by echocardiography and bioreactance at rest
and at peak dobutamine stress test in patients of HFpEF. Both these methods are non-invasive,
easily available and could potentially be used in wider clinical practice in cardiology where the 
use of gold standard invasive methods is not viable. This is particularly important in clinical 
settings where it is necessary to estimate the haemodynamic response to a physiological or 
pharmacological challenge, such as fluid responsiveness, passive leg raising, surgery, drug 
titration, and anaesthesia. The present findings suggest that echocardiography cannot be used
interchangeably with bioreactance. However, this should not preclude its use in clinical 
practice, where its advantages over the gold-standard methods have been well documented and
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Table 1. Patient demographic and clinical characteristics.
Demographics Mean  SD
Age (years) 61  7
Height (cm) 154 7
Weight (Kg) 67 15
Body surface area (m2) 1.66  0.19
Clinical Characteristics
NYHA class 1.3 0.47
Left ventricular ejection fraction (%) 54.45 3.03
Hypertension (%) 85
Diabetes mellitus (%) 35
Ischaemic heart disease (%) 20
ACEI/ARBs (%) 80
Beta blocker (%) 30
Diuretics (%) 35
Calcium channel blockers (%) 10
NYHA – New York Heart Association functional class; ACE- Angiotensin converting 










    
    
       
       
        
       
       
        
    
       
       
        
       
       





Table 2: Comparison of echocardiography and bioreactance measurements rest and peak 
dobutamine stress test.
Echocardiography Bioreactance P value
Rest
Heart rate (beats/min) 78 15 78 16 0.93
Cardiac output (L/min) 4.61 1.09 4.15 1.23 0.07
Cardiac index (L/m2/min) 2.80 0.76 2.49 0.61 0.08
Stroke volume (ml) 59.48 11.88 53.78 13.86 0.06
Systolic Blood pressure (mm Hg) 121.33 8.34 117.87 17.61 0.29
Diastolic Blood pressure (mm Hg) 76.67 4.88 69.33 10.06 < 0.01
Peak stress test
Heart rate (beats/min) 103 15 102 16 0.54
Cardiac output (L/min) 7.06 1.43 5.71 1.59 < 0.01
Cardiac index (L/m2/min) 4.27 0.67 3.43 0.87 < 0.01
Stroke volume (ml) 67.77 15.66 58.57 21.22 < 0.01
Systolic Blood pressure (mmHg) 136.60 23.43 125.47 42.13 0.54













   
    
 
Figure 1: Relationship between echocardiography and bioreactance cardiac outputs at rest 
and peak dobutamine stress
Figure 2: Bland-Altman plot to demonstrate mean difference and upper and lower limits of 
agreement between bioreactance and echocardiography derived cardiac outputs measured at 
rest (A) and peak dobutamine stress test (B). 
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